NEW
YORK, May 18, 2022 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Axsome
Therapeutics, Inc..
Shareholders who purchased shares of AXSM during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/axsome-therapeutics-inc-loss-submission-form/?id=27356&from=4
CLASS PERIOD: December 30,
2019 to April 22, 2022
ALLEGATIONS: The complaint alleges that during the class
period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (i) Axsome's chemistry,
manufacturing, and control ("CMC") practices were deficient with
respect to AXS-07, the Company's medicine for the acute treatment
of migraine, and its manufacturing process; (ii) as a result,
Axsome was unlikely to submit the AXS-07 New Drug Application
("NDA") on its initially represented timeline; (iii) the foregoing
CMC issues remained unresolved at the time that the U.S. Food and
Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv)
accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as
a result of all the foregoing, Axsome had overstated AXS-07's
regulatory and commercial prospects; and (vi) as a result, the
Company's public statements were materially false and misleading at
all relevant times.
DEADLINE: July 12, 2022
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/axsome-therapeutics-inc-loss-submission-form/?id=27356&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of AXSM during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is July 12, 2022. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law Firm is
committed to ensuring that companies adhere to responsible business
practices and engage in good corporate citizenship. The firm seeks
recovery on behalf of investors who incurred losses when false
and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-axsome-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-july-12-2022--nasdaq-axsm-301549357.html
SOURCE The Gross Law Firm